Toll-like receptor 7 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Toll-like receptor 7 shows approved-linked disease relevance led by actinic keratosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9NYK1. Start with actinic keratosis, then reuse UniProt Q9NYK1 as the stable protein anchor across project notes and exports.
Start with actinic keratosis, then reuse UniProt Q9NYK1 as the stable protein anchor across project notes and exports.
Toll-like receptor 7 shows approved-linked disease relevance led by actinic keratosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with actinic keratosis because it currently carries approved-linked support. Linked drugs include IMIQUIMOD, RESIQUIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyToll-like receptor 7
Review this target as Toll-like receptor 7, mapped to UniProt Q9NYK1. Sequence length is 1049 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Toll-like receptor 7 as ChEMBL target CHEMBL5936, mapped to UniProt Q9NYK1. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Toll-like receptor 7 is the right protein anchor across sources, using UniProt Q9NYK1 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why actinic keratosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Toll-like receptor 7 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9NYK1 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Toll-like receptor 7 |
| UniProt Accession | Q9NYK1 |
| Component Type | Protein |
| Sequence Length | 1049 aa |
Toll-like receptor 7
Review this target as Toll-like receptor 7, mapped to UniProt Q9NYK1. Sequence length is 1049 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Toll-like receptor 7 shows approved-linked disease relevance led by actinic keratosis. 5 more disease programs remain visible in the same review block.
Start review with actinic keratosis because it currently carries approved-linked support. Linked drugs include IMIQUIMOD, RESIQUIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5266091 | 10.15 | EC50 | 0.07 | Preclinical |
| CHEMBL5751106 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL5885111 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL5858961 | 10.05 | IC50 | 0.09 | Preclinical |
| CHEMBL5079910 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5940072 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL5267703 | 9.96 | EC50 | 0.11 | Preclinical |
| CHEMBL5921788 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL5998206 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL5976680 | 9.85 | IC50 | 0.14 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 165 | 1,072 | 6.5 |
| assay format | 40 | 4,200 | 8.0 |
| single protein format | 27 | 104 | 5.8 |
| tissue-based format | 15 | 29 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 23 | 84 | 5.8 |
| assay format | 12 | 57 | 7.3 |